Sanctuary site leptomeningeal metastases in HER-2 positive breast cancer: A review in the era of trastuzumab.

[1]  S. Culine,et al.  Intrathecal Trastuzumab Halts Progression of CNS Metastases in Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Hofer,et al.  Complement Activation and Rituximab Distribution in CNS NHL—Letter , 2015, Clinical Cancer Research.

[3]  J. Raizer,et al.  AT-47PHASE I TRIAL OF INTRATHECAL TRASTUZUMAB IN HER2 POSITIVE LEPTOMENINGEAL METASTASES , 2014 .

[4]  G. Yaghmour,et al.  Drug-Induced Aseptic Meningitis Associated With Intrathecal Trastuzumab , 2014, The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians.

[5]  M. Dimopoulos,et al.  Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis , 2013, Breast Cancer Research and Treatment.

[6]  C. Dumitrescu,et al.  Intrathecal Trastuzumab Treatment of the Neoplastic Meningitis due to Breast Cancer: A Case Report and Review of the Literature , 2013, Case reports in oncological medicine.

[7]  P. Venuturumilli,et al.  Rapid clinical and radiographic improvement after intrathecal trastuzumab and methotrexate in a patient with HER-2 positive leptomeningeal metastases , 2013, Acta oncologica.

[8]  S. Hofer,et al.  Intrathecal trastuzumab: dose matters , 2012, Acta oncologica.

[9]  D. Brandt.  Intrathecal trastuzumab: 46 months and no progression , 2012 .

[10]  Michal Mego,et al.  Intrathecal administration of trastuzumab with cytarabine and methotrexate in breast cancer patients with leptomeningeal carcinomatosis. , 2011, Breast.

[11]  C. Zielinski,et al.  Trastuzumab treatment in patients with breast cancer and metastatic CNS disease. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  L. Panasci,et al.  Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  N. Harbeck,et al.  Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report. , 2008, Anti-cancer drugs.

[14]  N. Harbeck,et al.  Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier , 2007, Anti-cancer drugs.

[15]  J. Baselga,et al.  Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  L. Laufman,et al.  Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. , 2001, Clinical breast cancer.